Ribbon Bio launched an early‑access program for a cell‑free manufacturing process that synthesizes long linear and circular DNA with claimed high accuracy, addressing demand from cell and gene therapy and mRNA vaccine developers. The Vienna‑based firm emphasized the product is free from bacterial proteins and endotoxins, easing regulatory and manufacturing hurdles for therapeutic applications. Ribbon highlighted demonstrated production of 11‑kb molecules with >90% guaranteed accuracy and average accuracy near 95% for linear DNA, positioning the platform for GMP transition and clinical‑grade material needs. Pricing tiers and R&D collaboration options were announced to support complex, GC‑rich or repetitive sequences. Long, high‑fidelity synthetic DNA is a bottleneck for next‑generation nucleic acid medicines; Ribbon’s cell‑free offering targets that market niche and could shorten timelines for personalized vaccines, long‑read constructs and advanced gene‑editing payloads.